Deuterium Metabolic Imaging to Assess Radiotherapy Changes in Glioblastoma Multiforme
Study Details
Study Description
Brief Summary
This is a feasibility single arm study designed for obtaining early data for optimization and evaluation of the clinical potential for a new MR technique using deuterated glucose. The purpose of the study is to investigate whether this technique is useful in metabolic imaging of glioblastoma multiforme (GBM) and whether radiochemotherapy (RCT) induced changes in the brain metabolism can be detected and might be predictive for treatment response. The study will include 10 patients with histologically verified GBM scheduled for standard RCT. Patients will have MRI scan performed before and within 8 weeks after starting RCT. The scans will include imaging after oral intake of deuterated glucose, so called deuterium metabolic imaging (DMI). Based on this study, the most optimal scanning technique, output variables of highest discriminative power with respect to RCT, and potential predictive markers for response will be selected for further clinical investigation.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| GBM patients, IDH-wt
|
Diagnostic Test: Deuterium metabolic imaging
MRI after oral administration of 75g of [6,6'-2H2]glucose.
|
Outcome Measures
Primary Outcome Measures
- Deuterium Metabolic Imaging [Imaging repeated twice with ~10 weeks between them.]
2H-glucose uptake and conversion to lactate and glx over 120 minutes in normal brain and tumor tissue. Before and after radiochemotherapy to measure the changes with therapy.
Secondary Outcome Measures
- Perfusion MRI [Imaging repeated twice with ~10 weeks between them.]
Dynamic contrast enhancement MRI using a gadolinium-based contrast agent.
- Microvascular diffusion MRI [Imaging repeated twice with ~10 weeks between them.]
Diffusion-weighted MRI.
- Amide proton transfer weighted MRI [Imaging repeated twice with ~10 weeks between them.]
APT-CEST MRI.
- Progression-free survival [Until an event (average 6 months) or closure of the protocol after 4 years.]
Time until progression or death.
- Overall survival [Until an event (average 15 months) or closure of the protocol after 4 years.]
Time until death.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients with newly diagnosed GBM IDHwt
-
Scheduled for long-course radiotherapy
-
At least 18 years of age
-
WHO performance status 0-1
-
Women who are not postmenopausal or surgically sterile must have a negative serum or urine pregnancy test performed at time of inclusion in the study. Safe and highly effective contraception must be used throughout the study meaning either hormonal anti-conception or an anti-fertility intrauterine device.
-
Danish speaking
-
Able and willing to comply after informed consent
Exclusion Criteria:
-
Subjects who are receiving any other investigational agents.
-
Previous or current treatment by radiation or chemotherapy.
-
History of alcohol abuse or illicit drug use.
-
Contraindications to MRI Pacemaker, neurostimulator or cochlea implant Metal foreign bodies such as fragments and irremovable piercings Unsafe medical implants Intracranial clips or coils Claustrophobia Largest circumference including arms > 160 cm
-
Contraindications to gadolinium contrast eGFR ≤ 30 mL/min/1.73m2 Previous adverse reactions to gadolinium
-
Not able or willing to receive radiotherapy
-
Predicted remaining survival <3 months
-
Insulin-treated diabetes
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Aarhus University | Aarhus | Denmark | 8200 |
Sponsors and Collaborators
- University of Aarhus
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- DMI-GBM